TFF Pharmaceuticals, Inc.
TFFP · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.07 | -0.19 | 0.34 |
| FCF Yield | -128.21% | -91.79% | -13.82% | -6.06% |
| EV / EBITDA | -0.35 | -0.48 | -6.03 | -13.76 |
| Quality | ||||
| ROIC | -226.13% | -137.35% | -81.92% | -49.72% |
| Gross Margin | 31.53% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.75 | 0.86 | 0.95 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 44.16% | 5.04% | -71.72% | -57.97% |
| Safety | ||||
| Net Debt / EBITDA | 0.26 | 0.52 | 1.09 | 1.89 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -480.43 | -864.60 | -4,892.22 | 0.00 |